Trump’s Bold Move: Science Funding Faces Massacre

Trump’s bold budget axe targets bloated science bureaucracies, slashing NIH by 40% and NSF by 56% to refocus federal dollars on core American priorities—but will Congress let thousands of grants vanish?

Story Snapshot

NIH funding drops to $41 billion, a $5 billion cut from FY25 levels, consolidating 27 institutes into 22.
NSF faces 56% reduction to $3.9 billion, dropping competitive grant awards to just 7% success rate.
2025 grant freezes already terminated 5,300 projects worth over $5 billion in unspent funds.
Eliminates institutes like Fogarty International Center and National Institute on Minority Health.
Congress from both parties likely to reject, preserving bipartisan science funding tradition.

Timeline of Aggressive Funding Reforms

Trump administration froze or terminated 5,300 NIH and NSF grants in 2025, affecting over $5 billion in unspent funds and halting more than 3,800 projects by November. Researchers lost mid-stream funding for cancer studies and infectious disease work. This set the stage for deeper cuts. April 2026 brought the FY2027 proposal: NIH at $41 billion, down $5 billion; NSF slashed to $3.9 billion. ARPA-H funding fell from $1.5 billion to $945 million. These moves prioritize efficiency over expansion.

Targeted Eliminations Reshape Agency Structure

NIH consolidates from 27 institutes to 22 centers, eliminating the National Center for Complementary and Integrative Health, Fogarty International Center, and National Institute on Minority Health and Health Disparities. Substance abuse research institutes merge. National Institute of Environmental Health Sciences relocates to CDC. NSF proposes a 7% award rate, rejecting 93% of competitive grants. Administrative functions bear the brunt, aligning with goals to trim bureaucracy while realigning priorities.

Stakeholders Brace for Congressional Battle

Trump administration pushes reduced spending and realigned priorities. Congress holds approval power; lawmakers from both parties anticipate rejecting the proposal. NIH and NSF leaders manage restructuring. Biomedical researchers voice deep concern over grant losses. Academic institutions face revenue shortfalls. Scientific organizations like the American Society for Biochemistry and Molecular Biology decry erasure of bipartisan support.

Short-Term Disruptions Hit Researchers Hard

Thousands of grants terminate immediately, displacing scientists mid-project. Universities lose research capacity and indirect cost recovery. Northwestern’s Lurie Cancer Center alone forfeited $77 million in frozen funds. NSF’s low award rate crushes proposals. Public health surveillance weakens; vaccine development slows. STEM diversity initiatives like NSF’s INCLUDES lose $9 million. Pharmaceutical pipelines face upstream delays from fewer discoveries.

Long-Term Risks to U.S. Innovation Edge

America risks losing global scientific leadership as researchers exodus to foreign labs. Disease research stalls on cancer, infections, and pandemics. Infrastructure crumbles without investments. Environmental and minority health programs vanish, though cuts target DEI and vaccine hesitancy studies—areas conservatives view as wasteful. Frieden’s “assault on science” claim overstates; facts show bipartisan history rejected similar Trump proposals before, prioritizing fiscal discipline and common-sense reforms over unchecked growth.